BSX
The good news: the quarter showed up
Boston Scientific came in with Q1 2026 EPS of $0.80, ahead of the Street’s $0.78 call. Revenue landed right on the estimate at $5.29 billion, which is basically the corporate version of showing up on time and wearing the right shoes — not flashy, but solid.
Guidance: the part investors actually zoom in on
The company also nudged out guidance for the rest of 2026. Management now sees Q1 EPS in the $0.780–$0.800 range and full-year EPS in the $3.430–$3.490 range. That’s the sort of update that tells investors the business isn’t just coasting on one good quarter.
But the stock has some static on the line
Even with the earnings beat, Boston Scientific is dealing with a fresh pile of headline risk. A class-action filing is adding legal noise, and while that doesn’t always hit fundamentals immediately, it can absolutely keep sentiment jumpy when traders are looking for reasons to flinch.
The rest of the tape
There’s also a fun little side quest in the article: AE Wealth Management piled into BSX in Q4, while CEO Michael Mahoney sold shares back in February. None of that changes the operating story by itself, but it does remind you that the stock is getting plenty of attention from both institutions and insiders.
Big picture: Boston Scientific is still doing what investors want most — beating expectations and lifting guidance — but the market may stay a little grumpy until the legal clouds clear.